Bio-Rad Laboratories Inc
$ 352.47
2.93%
07 Aug - close price
- Market Cap 9,432,660,000 USD
- Current Price $ 352.47
- High / Low $ 353.33 / 339.18
- Stock P/E 41.66
- Book Value 268.30
- EPS 8.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.02 %
- ROE 0.03 %
- 52 Week High 353.33
- 52 Week Low 236.73
About
Bio-Rad Laboratories, Inc. is an American developer and manufacturer of specialized technological products for the life science research and clinical diagnostics markets.
Analyst Target Price
$329.00
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-04 | 2026-04-30 | 2026-02-12 | 2025-10-29 | 2025-07-31 | 2025-05-01 | 2025-02-13 | 2024-10-30 | 2024-08-01 | 2024-05-07 | 2024-02-15 | 2023-10-26 |
| Reported EPS | 2.62 | 1.89 | 2.51 | 2.26 | 2.61 | 2.54 | 2.9 | 2.01 | 3.11 | 2.29 | 3.1 | 2.33 |
| Estimated EPS | 2.34 | 1.99 | 2.7 | 1.93 | 1.75 | 1.78 | 2.88 | 1.18 | 2.02 | 2.14 | 2.87 | 2.81 |
| Surprise | 0.28 | -0.1 | -0.19 | 0.33 | 0.86 | 0.76 | 0.02 | 0.83 | 1.09 | 0.15 | 0.23 | -0.48 |
| Surprise Percentage | 11.9658% | -5.0251% | -7.037% | 17.0984% | 49.1429% | 42.6966% | 0.6944% | 70.339% | 53.9604% | 7.0093% | 8.0139% | -17.0819% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BIO
2026-08-05 00:15:20
Bio-Rad Laboratories reported flat net sales of $651.0 million in Q2 2026, with a significant net income of $371.4 million driven by a large fair-value gain on equity securities and a loan receivable, primarily related to its Sartorius investment. However, the first half of 2026 saw a net loss of $155.7 million due to a $280.2 million fair-value loss on these assets. The company announced a restructuring plan starting in July 2026, expected to incur $80-90 million in pre-tax charges through 2027, and maintains strong liquidity with $1.62 billion in cash and no borrowings on its credit facility.
2026-07-29 20:40:10
This article provides an AI-generated analysis for Bio-rad Laboratories Inc. Class A (NYSE: BIO), focusing on institutional trading strategies based on sentiment and price positioning. It outlines specific long and short trading strategies with entry zones, targets, and stop losses, along with a multi-timeframe signal analysis for near, mid, and long-term horizons. The analysis emphasizes strong near and mid-term sentiment, suggesting potential for extended positive momentum.
2026-07-28 19:11:30
Eva Anette Engelhardt, EVP and President of Bio-Rad Laboratories' Clinical Diagnostics Group, recently acquired 246 shares of Class A common stock through restricted stock unit vesting. Concurrently, she sold 89 shares at $314.46 each. This transaction offers transparency into executive compensation and stock ownership practices at the company.
2026-07-23 05:43:28
Bio-Rad Laboratories (BIO) stock has declined 57.1% over five years, yet its current price of US$301.70 appears fairly valued according to Discounted Cash Flow (DCF) estimates which suggest an intrinsic value of $291 per share. However, its P/E ratio of 47.8x is higher than the Life Sciences industry average of 38.0x, indicating it might be overvalued based on earnings. The launch of Vericheck ddPCR kits could support future demand, but investors are already paying a premium.
2026-07-17 03:09:57
This article lists various Exchange Traded Funds (ETFs) that hold Bio-Rad Laboratories, Inc. Class A stocks, sorted by market value. It provides key financial data for each ETF, including issuer, management style, expense ratio, assets under management (AUM), price, change percentage, and 3-year total return. The information aims to help investors identify opportunities and understand the risk profiles associated with these ETFs.
2026-07-13 02:40:01
Bio-Rad Laboratories (BIO) has launched new QX700 System-compatible Vericheck ddPCR Kits for quality control in cell and gene therapy, potentially impacting investor assessment of the stock. While the company's shares show modest recent momentum and analyst targets are largely met, Simply Wall St's narrative suggests a fair value of $293, making the current price of $296.11 slightly overvalued. The fair value assessment is based on strong recurring consumables sales and an optimistic earnings multiple, though softer instrument demand and policy shifts in China pose potential challenges.
